These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7678041)

  • 21. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
    Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry.
    Deshmukh N; Scotson J; Dodson AR; Smith PH; Ke Y; Foster CS
    Br J Urol; 1997 Dec; 80(6):869-74. PubMed ID: 9439399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunohistochemical analysis with anti-cytokeratin antibody in the prostatic epithelium].
    Yamanaka Y; Ishida H; Okada K; Nemoto N
    Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):545-53. PubMed ID: 11517564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
    Pacelli A; Bostwick DG
    Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
    Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
    Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
    De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
    Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
    Bostwick DG; Qian J; Maihle NJ
    Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue.
    Rubenstein M; Shaw MW; Ray V; Dubin A; McKiel CF; Guinan P
    Prostate; 1989; 14(4):383-8. PubMed ID: 2473461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
    Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
    Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of annexins I, II, IV and VII in whole prostate sections from radical prostatectomy patients.
    Lehnigk U; Zimmermann U; Woenckhaus C; Giebel J
    Histol Histopathol; 2005 Jul; 20(3):673-80. PubMed ID: 15944914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma.
    Helpap B; Riede C
    Pathol Res Pract; 1995 Jun; 191(5):381-90. PubMed ID: 7479355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in sphingomyelin and fatty acids in human benign prostatic hyperplasia and prostatic cancer.
    Narayan P; Dahiya R
    Biomed Biochim Acta; 1991; 50(9):1099-108. PubMed ID: 1724598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
    Kyprianou N; Tu H; Jacobs SC
    Hum Pathol; 1996 Jul; 27(7):668-75. PubMed ID: 8698310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate.
    Helpap B
    Pathol Res Pract; 1995 Sep; 191(9):904-7. PubMed ID: 8606872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate.
    Shah IA; Schlageter MO; Stinnett P; Lechago J
    Mod Pathol; 1991 Mar; 4(2):220-4. PubMed ID: 1710806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate.
    Kumar VL; Majumder PK; Gujral S; Kumar V
    Cancer Lett; 1998 Dec; 134(2):177-80. PubMed ID: 10025878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in biomarker expression in the development of prostatic adenocarcinoma.
    Myers RB; Grizzle WE
    Biotech Histochem; 1997 Mar; 72(2):86-95. PubMed ID: 9152521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
    Cardillo MR; Ippoliti F
    Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study.
    Giri DK; Wadhwa SN; Upadhaya SN; Talwar GP
    Prostate; 1993; 23(4):329-36. PubMed ID: 7505056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate.
    Lee HK; Driscoll D; Asch H; Asch B; Zhang PJ
    Prostate; 1999 Jun; 40(1):14-9. PubMed ID: 10344719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.